Loading clinical trials...

QUILT-2.017: Phase 1b/2 Study of AMG 479 in Combination With Paclitaxel and Carboplatin for 1st Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer | Clinical Trials | Clareo Health

TERMINATEDPHASE1/PHASE2

QUILT-2.017: Phase 1b/2 Study of AMG 479 in Combination With Paclitaxel and Carboplatin for 1st Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer

A Phase 1b/2 Study of AMG 479 in Combination With Paclitaxel and Carboplatin for the First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer

NCT00807612•NantCell, Inc.

View on ClinicalTrials.gov

Summary

This is a global, multicenter, 2-part, open-label phase 1b and single-arm phase 2 study designed to evaluate the safety and efficacy of AMG 479 in combination with paclitaxel and carboplatin for the first-line treatment of advanced squamous non-small cell lung carcinoma.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Histologically or cytologically confirmed advanced squamous NSCLC
•Measurable disease as defined per modified RECIST criteria
•ECOG performance status of 0 or 1
•≥18 years old
•Adequate glycemic function, for subjects with known diabetes

Exclusion Criteria

•Untreated or symptomatic central nervous system (CNS) metastases
•Prior anti-cancer therapy as follows: Any prior chemotherapy for squamous NSCLC; Any prior adjuvant or neoadjuvant chemotherapy for squamous NSCLC; Any prior chemoradiation for squamous NSCLC; Central (chest) radiation therapy ≤ 28 days prior to enrollment, radiation therapy for peripheral lesions≤14 days prior to enrollment for squamous NSCLC

Locations (25)

Research Site

Fayetteville, Arkansas, United States

Research Site

Fayetteville, Arkansas, United States

Research Site

Fort Wayne, Indiana, United States

Research Site

Fort Wayne, Indiana, United States

Research Site

Indianapolis, Indiana, United States

Research Site

Indianapolis, Indiana, United States

Research Site

Indianapolis, Indiana, United States

Research Site

Lafayette, Indiana, United States

Research Site

Lafayette, Indiana, United States

Research Site

New Albany, Indiana, United States

Key Dates

Start Date

January 1, 2009

Primary Completion Date

August 1, 2010

Completion Date

August 1, 2010

Last Updated

September 25, 2024

Enrollment

ACTUAL participants

Conditions

Advanced Squamous Non-Small Cell Lung Cancer

Interventions

AMG 479

BIOLOGICAL

AMG 479

BIOLOGICAL

Carboplatin

DRUG

AMG 479

BIOLOGICAL

Paclitaxel

DRUG

A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

NCT02941601

Locally Advanced Squamous Non-Small Cell Lung CancerMetastatic Squamous Non-Small Cell Lung Cancer

View study

UNKNOWNPHASE1

Efficacy and Safety of SCT200 in Patients With Advanced Squamous Non-small Cell Lung Cancer

NCT03808701

Advanced Squamous Non-small Cell Lung Cancer

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 25, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions